Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04986865 · ClinicalTrials.gov registry record · Phase 1
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
A Phase 1 study, sponsored by Antengene Biologics Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04986865 is a Phase 1 study that was terminated before completion, run by Antengene Biologics Limited. The registered enrollment target is 31 participants.
The verdict
NCT04986865, a Phase 1 study, was terminated before completion, sponsored by Antengene Biologics Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.
Interventions
- DRUG ATG-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04986865
The ClinicalTrials.gov registry entry for NCT04986865 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antengene Biologics Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATG-101 is the first listed.
NCT04986865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04986865 about?
NCT04986865 is a clinical study titled "A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas". This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.
What is the current status of trial NCT04986865?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-12-15. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT04986865?
The interventions under investigation include: ATG-101 (DRUG).
Who is sponsoring clinical trial NCT04986865?
This trial is sponsored by Antengene Biologics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.